News Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases January 5, 2023 By Ellen Leventry This article is sourced from an external publication. Read the original → ← PreviousOligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 MeetingsNext →Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
